Leon Verbruggen

TL;DR: Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic Acid might be an effective treatment for postmenopausal osteoporosis.

TL;DR: The detailed description of such a large set of CED patients will be of value in establishing the correct diagnosis, genetic counselling, and treatment, and the overview of possible treatments, diagnostic guidelines, and considerations for prenatal testing is provided.

TL;DR: TGFB1 was evaluated as a candidate gene for causing CED because this region contains the gene encoding transforming growth factor-β1, an important mediator of bone remodelling.

TL;DR: The data suggest that RANK is not directly involved in PDB in a set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in P DB patients as compared with the random population.

TL;DR: It is proved that the momentary DAS28 score correlates best with the treating rheumatologist's decision to increase the dose of infliximab (+MTX), which indicates an insufficient response to inflIXimab at 3 mg/kg in patients with RA.